Additionally, 55% had elevated p‐tau217, the most reliable blood biomarker of AD; this degree of elevated p‐tau217 is greater than the 22% reported in a cohort recruited from the general population with similar age, sex, and APOE ε4 prevalence.35 This evidence concerns the gene APOE and Alzheimer disease.